專利名稱::苯甲酰胍-曲美他嗪的偶聯(lián)物、其制備方法及其醫(yī)藥用途的制作方法
技術(shù)領(lǐng)域:
:本發(fā)明涉及藥物化學(xué)領(lǐng)域,具體涉及一類曲美他嗪偶聯(lián)的苯甲酰胍衍生物、它們的制備方法、含有這些化合物的藥用組合物以及它們的醫(yī)藥用途,特別是作為抗心肌缺血再灌注損傷藥物的用途。
背景技術(shù):
:Na7H+交換器(Na+/H+exchanger,NHE)是一種在許多哺乳動物的各類細(xì)胞中均有表達(dá)的蛋白質(zhì),目前已經(jīng)有9個NHE亞型被確證,分別是NHE19,它們分布于人體各器官。在哺乳動物的心肌細(xì)胞上以NHE1為主,其在心肌缺血再灌注過程中起著重要作用。NHE1抑制劑通過抑制Na+/H+交換,避免過多Na+進(jìn)入細(xì)胞內(nèi),進(jìn)而使Na+/Ca2+交換減少,防止Ca2+過度增加引起細(xì)胞攣縮,壞死。NHE-1抑制劑還通過抑制Na7H+交換,減少細(xì)胞內(nèi)的Na+濃度,使?jié)B透壓下降,防止水分進(jìn)入細(xì)胞內(nèi),因此能防止或減輕缺血后微血管內(nèi)皮細(xì)胞腫脹,防止細(xì)胞壞死。曲美他嗪(Trimetazidine)是一種代謝類藥物,它可通過選擇性抑制長鏈3_酮酰CoA硫解酶,減少脂肪酸氧化,激活葡萄糖氧化,從而更有效地利用有限的氧產(chǎn)生ATP,改善心肌缺血。苯甲酰胍衍生物與曲美他嗪的作用機(jī)制不同,但它們對大鼠心肌缺血再灌注損傷均具有保護(hù)作用。
發(fā)明內(nèi)容本發(fā)明公開了一類苯甲酰胍-曲美他嗪的偶聯(lián)物,經(jīng)血小板腫脹試驗(PlateletSwellingAssay,PSA)顯示,本發(fā)明化合物對NHE1有較強(qiáng)的抑制作用,明顯強(qiáng)于陽性藥卡立泊來德。本發(fā)明的化合物通式I如下其中n=25;R代表氫、氯、溴、二溴、硝基、QCe烷基磺酰胺基、對甲苯磺酰胺基、噻吩-l-甲酰胺基、噻吩_2-甲酰胺基、2_甲基噻吩-1-甲酰胺基、QC6烷基酰胺基或R1取代的苯甲酰胺基。其中R1代表氫、鹵素、硝基、氰基、三氟甲基、羥基、QC6烷基、QC6烷氧基或亞甲二氧基,這些W基團(tuán)是單個取代、任意兩個同時取代或任意三個同時取代。R基團(tuán)處于酰胍基的鄰位或間位。n優(yōu)選代表2。R優(yōu)選代表對甲苯磺酰胺基、噻吩-1-甲酰胺基、噻吩_2-甲酰胺基、2_甲基噻吩-1-甲酰胺基、2_硝基苯甲酰胺基、3_硝基苯甲酰胺基、4_硝基苯甲酰胺基、4_三氟甲基苯甲酰胺基、2_乙基苯甲酰胺基、2,4-二氯苯甲酰胺基、2_甲基-3-硝基苯甲酰胺基、2,4-二氯-5-甲氧基苯甲酰胺基或2-甲氧基-3,4,5-三氟苯甲酰胺基。R基團(tuán)優(yōu)選處于酰胍基的間位。根據(jù)本發(fā)明,藥學(xué)上可接受的鹽包括通式I化合物與下列酸形成的酸加成鹽鹽酸、氫溴酸、硫酸、碳酸、檸檬酸、琥珀酸、酒石酸、磷酸、乳酸、丙酮酸、乙酸、馬來酸、蘋果酸、甲磺酸、苯磺酸、對甲苯磺酸、阿魏酸或煙酸。本發(fā)明部分化合物的化學(xué)結(jié)構(gòu)是,這些化合物最后括號中是該化合物的代號,這些代號與藥理試驗及實施例中的代號相同,表示同一個化合物3-硝基-4-(2-(4-(2,3,4-三甲氧基節(jié)基)哌嗪-l-基)乙氧基)-苯甲酰胍(I-l)4-(2-(4-(2,3,4-三甲氧基節(jié)基)哌嗪_1_基)乙氧基)苯甲酰胍(1-2)3-溴-4-(2-(4-(2,3,4-三甲氧基節(jié)基)哌嗪_1_基)乙氧基)苯甲酰胍(1-3)3,5-二溴-4-(2-(4-(2,3,4-三甲氧基節(jié)基)哌嗪-l-基)乙氧基)苯甲酰胍(1-4)4-(2-(4-(2,3,4-三苯甲酰胍(1-5)4-(2-(4-(2,3,4-三(1-6)4-(2-(4-(2,3,4-三基)苯甲酰胍(1-7)4-(2-(4-(2,3,4-三苯甲酰胍(1-8)4-(2-(4-(2,3,4-三基)苯甲酰胍(1-9)4-(2-(4-(2,3,4-三氟苯甲酰胺基)苯甲酰胍(I4-(2-(4-(2,3,4-三苯甲酰胍(H1)4-(2-(4-(2,3,4-三苯甲酰胍(H2)4-(2-(4-(2,3,4-三甲酰胺基)苯甲酰胍(1-13)4-(2-(4-(2,3,4-三甲酰胺基)苯甲酰胍(1-14)4-(2-(4-(2,3,4-三苯甲酰胍(H5)4-(2-(4-(2,3,4-三苯甲酸酰胍(1-16)三甲氧基節(jié)基)哌嗪-l-基)乙氧基)-3-(4-氯苯甲酰胺基)三甲氧基節(jié)基)哌嗪-l-基)乙氧基)-3-苯甲酰胺基苯甲酰胍三甲氧基節(jié)基)哌嗪-l-基)乙氧基)-3-(4-甲氧基苯甲酰胺三甲氧基節(jié)基)哌嗪-l-基)乙氧基)-3-(4-甲基苯甲酰胺基)三甲氧基節(jié)基)哌嗪-l-基)乙氧基)-3-(2,4-二氯苯甲酰胺三甲氧基芐基)哌嗪-l-基)乙氧基)-3-(2-甲氧基-3,4,5-三-10)三甲氧基節(jié)基)哌嗪-l-基)乙氧基)-3-(2-硝基苯甲酰胺基)三甲氧基節(jié)基)哌嗪-l-基)乙氧基)-3-(4-乙基苯甲酰胺基)三甲氧基節(jié)基)哌嗪-l-基)乙氧基)-3-(3-甲基-4-硝基苯三甲氧基節(jié)基)哌嗪-l-基)乙氧基)_3-(2-甲基-3-硝基苯三甲氧基節(jié)基)哌嗪-l-基)乙氧基)-3-(4-氰基苯甲酰胺基)三甲氧基節(jié)基)哌嗪-l-基)乙氧基)-3-(3-甲基苯甲酰胺基)4-(2-(4-(2,3,4-三甲氧基節(jié)基氯苯甲酰胺基)苯甲酰胍(1-17)4-(2-(4-(2,3,4-三甲氧基節(jié)基(H8)4-(2-(4-(2,3,4-三甲氧基節(jié)基胺基)苯甲酰胍(H9)4-(2-(4-(2,3,4-三甲氧基節(jié)基甲酰胍(1-20)4-(2-(4-(2,3,4-三甲氧基節(jié)基甲酰胍(1-21)4-(2-(4-(2,3,4-三甲氧基節(jié)基胺基)苯甲酰胍(1-22)4-(2-(4-(2,3,4-三甲氧基節(jié)基:苯甲酰胍(1-23)4-(2-(4-(2,3,4-三甲氧基節(jié)基苯甲酰胍(1-24)4-(2-(4-(2,3,4-三甲氧基節(jié)基苯甲酰胍(1-25)4-(2-(4-(2,3,4-三甲氧基節(jié)基苯甲酰胍(1-26)4-(2-(4-(2,3,4-三甲氧基節(jié)基苯甲酰胍(1-27)4-(3-(4-(2,3,4-三甲氧基節(jié)基:苯甲酰胍(1-28)4-(3-(4-(2,3,4-三甲氧基節(jié)基基)苯甲酰胍(1-29)4-(3-(4-(2,3,4-三甲氧基節(jié)基基)苯甲酰胍(1-30)4-(3-(4-(2,3,4-三甲氧基節(jié)基甲酰胺基)苯甲酰胍(1-31)4-(3-(4-(2,3,4-三甲氧基節(jié)基:苯甲酰胍(1-32)4-(3-(4-(2,3,4-三甲氧基節(jié)基:苯甲酰胍(1-33)4-(3-(4-(2,3,4-三甲氧基節(jié)基基)苯甲酰胍(1-34)4-(3-(4-(2,3,4-三甲氧基節(jié)基胺基)苯甲酰胍(1-35)4-(3-(4-(2,3,4-三甲氧基節(jié)基:哌嗪-l-基)乙氧基)_3-(3-甲氧基-2,4-二哌嗪-l-基)乙氧基)_3-乙酰胺基苯甲酰胍哌嗪-l-基)乙氧基)-3-(4-三氟甲基苯甲酰哌嗪-1-基)乙氧基)_3-(2-噻吩酰胺基)苯哌嗪-1-基)乙氧基)_3-(3-噻吩酰胺基)苯哌嗪-l-基)乙氧基)_3-(3-甲基-2-噻吩酰哌嗪-l-基)乙氧基)-3-(4-甲基苯磺酰胺基)哌嗪-l-基)乙氧基)-3-(鄰氯苯甲酰胺基)哌嗪-l-基)乙氧基)-3-(鄰溴苯甲酰胺基)哌嗪-l-基)乙氧基)-3-(鄰氟苯甲酰胺基)哌嗪-l-基)乙氧基)-3-(鄰碘苯甲酰胺基)哌嗪-l-基)丙氧基)-3-(2-硝基苯甲酰胺基)哌嗪-l-基)丙氧基)-3-(2,4-二氯苯甲酰胺哌嗪-l-基)丙氧基)-3-(4-甲氧基苯甲酰胺哌嗪-l-基)丙氧基)_3-(2-甲基-3-硝基苯哌嗪-l-基)丙氧基)-3-(4-氰基苯甲酰胺基)哌嗪-l-基)丙氧基)-3-(4-乙基苯甲酰胺基)哌嗪-l-基)丙氧基)-3-(2,6-二氯苯甲酰胺哌嗪-l-基)丙氧基)-3-(4-三氟甲基苯甲酰哌嗪-l-基)丙氧基)-3-苯甲酰胺基苯甲酰胍[OO52]4-(3-(4-(2,3,4-三甲氧基芐基)哌嗪-l-基)丙氧基)-3-(3-噻吩酰胺基)苯甲酰胍(1-37)4-(3-(4-(2,3,4-三甲氧基芐基)哌嗪_1_基)丙氧基)_3_(2-噻吩酰胺基)苯甲酰胍(1-38)4-(3-(4-(2,3,4-三甲氧基節(jié)基)哌嗪_1_基)丙氧基)_3-(3-甲基_2_噻吩酰胺基)苯甲酰胍(1-39)4-(3-(4-(2,3,4-三甲氧基節(jié)基)哌嗪-l-基)丙氧基)_3_(4-甲基苯磺酰胺基)苯甲酰胍(1-40)本發(fā)明通式I化合物的制備方法如下當(dāng)R代表氫、氯、溴、二溴、硝基時,合成路線如下當(dāng)R代表QCe烷基磺酰胺基、對甲苯磺酰胺基、噻吩-1_基酰胺基、噻吩_2_基酰胺基、2_甲基噻吩-1-基酰胺基、QC6烷基酰胺基、苯甲酰胺基,或由下列基團(tuán)取代的苯甲酰胺基鹵素、QC6烷基、羥基、QC6烷氧基、硝基、氰基、三氟甲基時,合成路線如下為測定本發(fā)明化合物對NHE1活性的影響,進(jìn)行了血小板腫脹試驗(PlateletSwellingAssay,PSA)。將取自大鼠的血小板富集血槳(Platelet-richplasma,PRP)加入丙酸鈉介質(zhì)中,細(xì)胞NHE被激活,H+被轉(zhuǎn)運(yùn)到細(xì)胞外,同時細(xì)胞內(nèi)Na+增加。這一過程引起了細(xì)胞的滲透壓改變,為了恢復(fù)細(xì)胞內(nèi)正常滲透壓,細(xì)胞外液進(jìn)入細(xì)胞,導(dǎo)致細(xì)胞腫脹。血小板的這種腫脹引起了光密度(0D)降低。以卡立泊來德為陽性對照,通過PSA對目標(biāo)化合物的NHE1抑制活性進(jìn)行評估。繪制濃度_抑制率曲線,確定抑制50%細(xì)胞腫脹的藥物濃度(IC5。)。實驗參考Rosskopf等人(Hypertens.1991,9(3):231237)的方法:取大鼠眼底血5mL/只,加入含有0.25mLACD溶液的塑料試管中。室溫下(25°C)150g離心15min,取上2/3血槳,即血小板富集血槳(Platelet-richplasma,PRP)用于血小板腫脹試驗(PlateletSwellingAssay,PSA)。準(zhǔn)備好的血小板須在4h內(nèi)使用。受試藥物用匿SO溶解,加入標(biāo)準(zhǔn)介質(zhì)稀釋,最終匿SO含量均小于10—4mol/L。每個藥物測試6組濃度,每組測定三次。光密度(Opticaldensity,OD)由多掃描分光光度計測定。將175iiL丙酸鈉介質(zhì)及25iiL受試樣品或標(biāo)準(zhǔn)介質(zhì)加入96孔板(lcmpathlength),預(yù)熱至37。C后,加入50iiLPRP。測定在550nm處的0D值變化,每隔7.5s記錄一個點,共記錄2min。計算方法OD值的變化符合單指數(shù)曲線,方程為OD(t)=OD(t=。)e—kt。其中t表示時間,單位是s;k為OD下降速率常數(shù),即腫脹速率常數(shù)。未加藥的對照組kmax值為最大腫脹速率常數(shù)。用10—5mol/L卡立泊來德所得kmin值作為基線對照,來表征非NHE激活引起的OD值變化,認(rèn)為該濃度下NHE1的活性達(dá)到完全抑制。對測得的OD值取自然對數(shù),以lnOD為Y軸,時間為X軸做散點圖,取前42s進(jìn)行線性回歸,所得斜率的絕對值即為k??鄢齥^后的k'與k^'相比得到百分速率常數(shù)(k%)。以受試藥物在不同濃度下的k^值為Y軸,與其相應(yīng)的濃度為X軸進(jìn)行非線性回歸分析(GraphpadPrismsoftware)擬合S曲線,對曲線進(jìn)行計算得IC5。,即降低50%血小板腫脹的濃度。計算公式<formula>formulaseeoriginaldocumentpage8</formula>結(jié)果如下表1.本發(fā)明部分化合物抑制NHE1的IC5。值<table>tableseeoriginaldocumentpage8</column></row><table><table>tableseeoriginaldocumentpage9</column></row><table>藥理測試結(jié)果表明,本發(fā)明化合物對大鼠NHE1有不同程度的抑制作用,因此,本發(fā)明的化合物可以用于預(yù)防或治療心肌缺血-再灌注損傷有關(guān)的臨床病癥。這些病癥包括心律失常、心室纖維化、心肌梗、心絞痛、心力衰竭、充血性心力衰竭、心肌缺血、外周及中樞神經(jīng)系統(tǒng)缺血癥狀、中風(fēng)的缺血癥狀、外周組織器官及四肢缺血、休克、缺血或再灌注引起的組織器官急慢性損傷、失調(diào)或間接后遺癥。本發(fā)明的化合物還可以用于外科手術(shù)及器官移植以及移植器官的保存。本發(fā)明還提供了一種治療心肌缺血_再灌注損傷的藥物組合物,其中含有治療有效量的通式I化合物和藥學(xué)上可接受的載體。所述藥物組合物可以是普通片劑或膠囊、緩釋片劑或膠囊、控釋片劑或膠囊、口服液、注射劑等制劑學(xué)上常規(guī)的制劑形式?!愕?,本發(fā)明的苯甲酰胍衍生物用于治療時,人用劑量范圍為2mg2000mg/天。也可根據(jù)劑型的不同和疾病嚴(yán)重程度,使用劑量超出該范圍。具體實施方式實施例13-硝基-4-(2-(4-(2,3,4-三甲氧基節(jié)基)哌嗪-l-基)乙氧基)苯甲酰胍(H)的制備3-硝基-4-(2-溴乙氧基)苯甲酸乙酯(III-l)取3-硝基-4-羥基苯甲酸乙酯(11-1)2.lg(O.Olmol)溶于40ml無水乙腈中,攪拌溶解,加入10g過量研細(xì)的碳酸鉀粉末,攪拌,再一次性投入BrCH2CH2Br7.5g(0.04mol),升溫至回流,反應(yīng)4h。將反應(yīng)液過濾,旋干濾液,柱層析(洗脫劑石油醚丙酮=8:1)得淡黃色固體1.3g,收率41.1%.m,p.49-5(TCHNMR(300MHz,CDCl3),S(卯m):1.34(3H,t,J=7.2Hz,-CH3),3.65(2H,t,J=6.6Hz,_CH2_),4.284.38(4H,m,_CH2_),6.88(1H,d,J=8.7Hz,ArH),7.88(1H,dd,^=8.7Hz,J2=2.1Hz,ArH),8.02(1H,d,J=2.1Hz,ArH).3-硝基-4-(2-(4-(2,3,4-三甲氧基芐基)哌嗪_1_基)乙氧基)-苯甲酸乙酯(iv-i)的制備游離曲美他嗪的制備取鹽酸曲美他嗪3g(8.8mmo1)用10ml水溶解,再用40%的KOH調(diào)pH等于ll。乙酸乙酯萃取三次(10mlX3),合并酯層用飽和氯化鈉水溶液洗滌三次(20mlX3),測pH值近中性,無水硫酸鈉干燥過夜。過濾,減壓蒸除溶劑,得游離曲美他嗪,為淺黃色油狀物1.88g。取游離曲美他嗪油狀物1.8g(0.0067mol),攪拌溶解于無水乙腈10ml,室溫下,將ni-11.4g(0.0044mmol),用20ml無水乙腈溶解,加入反應(yīng)瓶中。隨后加入3.Og無水碳酸鉀粉末,升溫至回流,反應(yīng)4h。過濾,濾液蒸干,殘留物溶于乙酸乙酯中,用水洗去過量的曲美他嗪,酯層用無水硫酸鈉干燥,過濾,旋干得得淡黃色固體1.8g,收率81.2%.m.p.106-109。C.^NMR(300MHz,CDC13),S(ppm):1.36(3H,t,J=7.2Hz,_CH3),2.452.70(8H,m,-n二n-),2.88(2H,t,J=5.7Hz,_CH2_),3.49(2H,s,_CH2_),3.84(3H,s,_OCH3),3.86(3H,s,-OCH3),3.87(3H,s,_OCH3),4.21(2H,t,J=5.7Hz,_CH2-),4.34(2H,q,J=7.2Hz,-CH2_),6.63(1H,d,J=8.4Hz,ArH),6.91(1H,d,J=8.7Hz,ArH),6.98(1H,d,J=8.4Hz,ArH),7.90(1H,dd,^=8.7Hz,J2=2.1Hz,ArH),8.04(1H,d,J=2.1Hz,ArH).3-硝基-4-(2-(4-(2,3,4-三甲氧基節(jié)基)哌嗪_1_基)乙氧基)苯甲酸(V-l)的制備25ml茄形瓶中加入IV-10.76g(l.5mmo1),60%甲醇水溶液40ml,加熱至回流,樣品溶解后,加入碳酸鉀0.63g(4.5mmo1),反應(yīng)2小時,減壓蒸除甲醇,2%的稀鹽酸調(diào)pH約為7(等電點),白色固體析出,靜置,過濾,干燥,得白色固體O.55g,收率76.6X.m.p.163°C166°C.丄HNMR(300MHz,CDC13),S(ppm):2.903.10(8H,m,-n二n-),3.16(2H,t,J=5.7Hz,-CH2_),3.84(3H,s,_0CH3),3.86(3H,s,_0CH3),3.87(3H,s,_0CH3),3.90(2H,s,-CH2_),4.32(2H,t,_CH2-,J=5.7Hz),6.63(1H,d,J=8.7Hz,ArH),6.91(1H,d,J=8.7Hz,ArH),7.09(1H,d,J=8.7Hz,ArH),8.O(IH,dd,J丄=8.7Hz,J2=1.8Hz,ArH),8.34(1H,d,J=1.8Hz,ArH).取V-10.3g(0.63mmol)溶于2ml無水DMF中,加入1_羥基苯并三唑(HOBT)O.09g(0.66mmol)和1_乙基_3_(3-二甲胺基丙基)碳二亞胺鹽酸鹽(EDCI)O.13g(0.66,1),攪拌溶解后,加入2ml水,快速加入游離胍0.15g(2.54,1),室溫反應(yīng)2小時。將反應(yīng)液攪拌下倒入乙酸乙酯水(3:2)的混合溶液50ml中,乙酸乙酯萃取(30mlX3)。合并酯層,飽和氯化鈉水溶液洗滌(50mlX3),無水硫酸鎂干燥,過濾,濾液減壓蒸干得黃色油狀物,柱層析(洗脫劑乙酸乙酯甲醇三乙胺=15:i:o.i)分離,得黃色油狀物1-10.083g,產(chǎn)率25.5%.IR(cm—0:3365,2941,1708(C=0),1617,1538,1464,1356,1276,1102(OCH3),1042,756.丄HNMR(300MHz,CDC13),S(ppm):2.502.70(8H,m,-n二n-),2.88(2H,t,J=5.7Hz,_CH2-),3.50(2H,s,_CH2_),3.85(3H,s,_OCH3),3.86(3H,s,_OCH3),3.87(3H,s,-OCH3),4.27(2H,t,J=5.7Hz,_CH2_),6.64(1H,d,J=8.4Hz,ArH),7.O(IH,d,J=8.4Hz,ArH),7.04(1H,d,J=8.7Hz,ArH),8.29(1H,d,J=8.7Hz,ArH),8.66(1H,s,ArH).MS(ESI(+)70V)m/z517.2[M+H]+.以4-羥基苯甲酸乙酯為原料,類似化合物1-1的方法,得到化合物I-2,光譜數(shù)據(jù)見表2。以3-溴-4-羥基苯甲酸乙酯為原料,類似化合物1-1的方法,得到化合物1-3,光譜數(shù)據(jù)見表2。以3,5-二溴-4-羥基苯甲酸乙酯為原料,類似化合物1-1的方法,得到化合物I-4,光譜數(shù)據(jù)見表2。實施例24-(2-(4-(2,3,4-三甲氧基芐基)哌嗪_1_基)乙氧基)_3_(4-氯苯甲酰胺基)苯甲酰胍(1-5)的制備3-氨基-4-(2-(4-(2,3,4-三甲氧基芐基)哌嗪_1_基)乙氧基)-苯甲酸乙酯(VI-1)取IV-17.6g(0.015mol),溶于50%乙醇溶液100ml中,加入還原鐵粉6.7g(0.12mol),機(jī)械攪拌下升溫至回流,滴加lmol/L鹽酸lml,保溫攪拌lh,趁熱過濾,將濾液旋干得淡黃色固體7.Og,收率98%,m.p.124-126°C。'HNMR(300MHz,CDC13),S(卯m):1.36(3H,t,J=6.9Hz,_CH3),2.502.65(8H,m,-n二n-),2.83(2H,t,J=5.1Hz,_CH2_),3.51(2H,s,-CH2_),3.85(3H,s,_OCH3),3.87(3H,s,_OCH3),3.88(3H,s,_OCH3),4.16(2H,t,,J=5.lHz,-CH2_),4.31(2H,q,J=6.9Hz,_CH2_),6.63(1H,d,J=8.7Hz,ArH),6.77(1H,d,J=8.4Hz,ArH),6.90(1H,d,J=8.4Hz,ArH),7.387.45(2H,m,ArH)4-(2-(4-(2,3,4-三甲氧基芐基)哌嗪_1_基)乙氧基)_3_(4-氯苯甲酰胺基)苯甲酸乙酯(VII-5)的制備取VI-1lg(O.0021mol)溶于20ml二氯甲烷中,加入三乙胺(0.4ml),將4-氯苯甲酰氯0.55g(0.0031mol)溶于2ml二氯甲烷,在0-5t:下將其滴入反應(yīng)液中,滴畢反應(yīng)2小時。將反應(yīng)液用飽和碳酸氫鈉溶液洗(20mlX3),飽和氯化鈉溶液洗(20mlX3),無水硫酸鈉干燥,抽濾,旋干濾液,柱層析(洗脫劑石油醚丙酮三乙胺=4:i:o.i)分離得到黃色油狀物0.67g,收率51.8%.^NMR(300MHz,CDC13),S(卯m):1.40(3H,t,J=7.5Hz,-CH3),2.402.60(8H,m,—NZ>—),2.81(2H,t,J=5.4Hz,_CH2_),3.42(2H,s,-CH2_),3.85(3H,s,_OCH3),3.86(3H,s,_OCH3),3.87(3H,s,_OCH3),4.25(2H,t,J=5.4Hz,-CH2_),4.37(2H,q,J=7.5Hz,_CH2_),6.63(1H,d,J=8.7Hz,ArH),6.936.98(2H,m,ArH),7.47(2H,d,J=8.4Hz,ArH),7.83(1H,dd,^=8.7Hz,J2=2.1Hz,ArH),7.87(2H,d,J=8.4Hz,ArH),8.83(1H,s,ArH),9.12(1H,d,J=2.1Hz,NH)4-(2-(4-(2,3,4-三甲氧基芐基)哌嗪_1_基)乙氧基)_3_(4-氯苯甲酰胺基)苯甲酸(VIII-5)的制備以VII-5為原料,操作同V-l,得白色固體,收率75.5%.m.p.91-94。C.^NMR(300MHz,CDC13),S(ppm):2.552.75(8H,m,-n二n-),2.88(2H,t,J=5.4Hz,-CH2_),3.63(2H,s,_CH2_),3.86(3H,s,_OCH3),3.87(3H,s,_OCH3),3.88(3H,s,-OCH3),4.20(2H,t,J=5.4Hz,_CH2_),6.68(1H,d,J=8.4Hz,ArH),6.87(1H,d,J=8.lHz,ArH),7.05(1H,d,J=8.4Hz,ArH),7.32(2H,dd,^=7.8Hz,J2=1.8Hz,ArH),7.83(1H,d,J=8.4Hz,ArH),7.92(2H,d,J=8.1Hz,ArH),8.81(1H,s,ArH),9.11(1H,s,NH),9.55(1H,s,-COOH).以VIII-5為原料,操作同I-l,得白色固體I-9,收率50X,m.p.164-166°C。IR(cm—0:3433,2934,2825,1687(C=0),1536,1495,1353,1270,1096(OCH3),1012,787^NMR(300MHz,CDC13),S(ppm):2.352.55(8H,m,-n二n-),2.76(2H,t,J=5.lHz,-CH2_),3.40(2H,s,_CH2_),3.84(3H,s,_OCH3),3.85(3H,s,_OCH3),3.86(3H,s,-OCH3),4.24(2H,t,J=5.1Hz,_CH2_),6.63(1H,d,J=8.4Hz,ArH),6.93(1H,d,J=8.4Hz,ArH),6.98(1H,d,J=8.7Hz,ArH),7.49(2H,d,J=8.7Hz,ArH),7.87(2H,d,J=8.4Hz,ArH),7.95(1H,dd,^=8.7Hz,J2=1.8Hz,ArH),8.67(1H,d,J=1.8Hz,ArH),8.98(1H,s,NH)MS(ESI(+)70V)m/z625.2[M+H]+Anal.Calcd.forC31H37N606C1H20:C57.89,H6.11,N13.07;Found:C57.90,H5.94,N12.84。以VI-1和苯甲酰氯為原料,類似化合物1-5的方法,得到化合物I-6,光譜數(shù)據(jù)見表2。以VI-1和4-甲氧基苯甲酰氯為原料,類似化合物1-5的方法,得到化合物1-7,光譜數(shù)據(jù)見表2。以VI-1和4-甲基苯甲酰氯為原料,類似化合物1-5的方法,得到化合物1-8,光譜數(shù)據(jù)見表2。以VI-1和2,4-二氯苯甲酰氯為原料,類似化合物1-5的方法,得到化合物1-9,光譜數(shù)據(jù)見表2。以VI-1和2-甲氧基-3,4,5-三氟苯甲酰氯為原料,類似化合物1-5的方法,得到化合物I-10,光譜數(shù)據(jù)見表2。實施例34-(2-(4-(2,3,4-三甲氧基芐基)哌嗪-l-基)乙氧基)-3-(2-硝基苯甲酰胺基)苯甲酰胍(HI)的制備4-(2-(4-(2,3,4-三甲氧基芐基)哌嗪-l-基)乙氧基)-3-(2-硝基苯甲酰胺基)苯甲酸乙酯(VII-ll)的制備以VI-l和2-硝基苯甲酰氯為原料,操作同VII-5,得到黃色固體,收率35.1%,m.p.57-60°C。'HNMR(300MHz,CDC13),S(ppm):1.40(3H,t,J=7.2Hz,_CH3),2.202.50(8H,m,-n二n-),2.71(2H,t,J=5.1Hz,_CH2_),3.33(2H,s,_CH2_),3.85(3H,s,_0CH3),3.86(3H,s,-0CH3),3.87(3H,s,-0CH3),4.22(2H,t,J=4.8Hz,_CH2_),4.38(2H,q,J=7.2Hz,-CH2_),6.63(1H,d,J=8.4Hz,ArH),6.92(1H,d,J=8.4Hz,ArH),6.97(1H,d,J=8.4Hz,ArH),7.627.69(3H,m,ArH),7.86(1H,d,J=8.7Hz,ArH),8.II(IH,d,J=7.8Hz,ArH),8.98(1H,s,ArH),9.02(1H,s,NH)4-(2-(4-(2,3,4-三甲氧基芐基)哌嗪-l-基)乙氧基)-3-(2-硝基苯甲酰胺基)苯甲酸(VIII-11)的制備以VII-ll為原料,操作同V-l,得白色固體,收率89.7X,m.p.100_103°C。'HNMR(300MHz,CDC13),S(ppm):2.702.90(8H,m,-n二n-),3.06(2H,t,J=5.lHz,_CH2-),3.68(2H,s,_CH2_),3.85(3H,s,_OCH3),3.86(3H,s,_OCH3),3.87(3H,s,-OCH3),4.21(2H,t,J=5.lHz,_CH2_),6.65(1H,d,J=8.7Hz,ArH),6.80(1H,d,J=8.4Hz,ArH),7.04(1H,d,J=8.7Hz,ArH),7.527.59(2H,m,ArH),7.68(1H,dd,J丄=8.4Hz,J2=1.5Hz,ArH),7.89(1H,d,J=7.5Hz,ArH),7.96(1H,d,J=8.lHz,ArH),8.45(1H,s,ArH),8.86(1H,s,NH)以VIII-11為原料,操作同I-l,得黃色固體I-ll,收率36X,m.p.192_195°C。IR(cm—0:3386,2936,2822,1668(C=0),1528,1494,1344,1269,1098(OCH3),1010,783一HNMR(300MHz,CDC13),S(ppm):2.102.45(8H,m,-n二n-),2.63(2H,t,J=5.4Hz,-CH2_),3.24(2H,s,_CH2_),3.85(3H,s,_OCH3),3.86(3H,s,_OCH3),3.87(3H,s,-OCH3),4.22(2H,t,J=5.4Hz,_CH2_),6.61(1H,d,J=8.7Hz,ArH),6.88(1H,d,J=8.4Hz,ArH),7.03(1H,d,J=8.7Hz,ArH),7.647.75(3H,m,ArH),7.98(lH,d,J=8.7Hz,ArH),8.II(IH,d,J=7.8Hz,ArH),8.60(1H,s,ArH),9.51(1H,s,NH).13CNMR(500MHz,CDC13),S(ppm):52.3(哌嗪C),53.2(哌嗪C),55.9,56.3,60.8,61.2,67.6,107.0,114.6,122.8,123.8,124.6,124.9,127.1,127.5,128.8,131.0,132.8,133.7,142.3,147.3,151.6,152.5,152.9,162.9,164.6,176.2(C=0);MS(ESI(+)70V)m/z636.3[M+H]+Anal.Calcd.forC31H37N7080.5H20:C57.75,H5.94,N15.21;Found:C58.04,H6.12,N14.91以VI-1和4-乙基苯甲酰氯為原料,類似化合物1-5的方法,得到化合物I-12,光譜數(shù)據(jù)見表2。以VI-1和3-甲基-4-硝基苯甲酰氯為原料,類似化合物1-5的方法,得到化合物I-13,光譜數(shù)據(jù)見表2。以VI-1和2-甲基-3-硝基苯甲酰氯為原料,類似化合物1-5的方法,得到化合物I-14,光譜數(shù)據(jù)見表2。以VI-1和4-氰基苯甲酰氯為原料,類似化合物1-5的方法,得到化合物1-15,光譜數(shù)據(jù)見表2。以VI-1和3-甲基苯甲酰氯為原料,類似化合物1-5的方法,得到化合物I-16,光譜數(shù)據(jù)見表2。以VI-1和2,4_二氯-3-甲氧基苯甲酰氯為原料,類似化合物1-5的方法,得到化合物I-17,光譜數(shù)據(jù)見表2。以VI-1和乙酰氯為原料,類似化合物1-5的方法,得到化合物1-18,光譜數(shù)據(jù)見表2。以VI-l和4-三氟甲基苯甲酰氯為原料,類似化合物1-5的方法,得到化合物I-19,光譜數(shù)據(jù)見表2。以VI-1和噻吩-2-甲酰氯為原料,類似化合物1-5的方法,得到化合物1-20,光譜數(shù)據(jù)見表2。實施例44-(2-(4-(2,3,4-三甲氧基芐基)哌嗪-l-基)乙氧基)-3-(3-噻吩酰胺基)苯甲酰胍(1-21)的制備4-(2-(4-(2,3,4-三甲氧基芐基)哌嗪-l-基)乙氧基)-3-(3-噻吩酰胺基)苯甲酸乙酯(VII-21)以VI-1和噻吩-3-甲酰氯為原料,操作同VII-5,得黃色油狀物,收率31.5%.^NMR(500MHz,CDCl3),S(ppm):1.40(3H,t,J=7.1Hz,_CH3),2.452.65(8H,m,-n3>—),2.85(2H,t,J=5.4Hz,_CH2_),3.49(2H,s,_CH2_),3.85(3H,s,_0CH3),3.86(3H,s,-0CH3),3.87(3H,s,-0CH3),4.26(2H,t,J=5.4Hz,_CH2_),4.37(2H,q,J=7.lHz,-CH2_),6.63(1H,d,J=8.5Hz,ArH),6.956.99(2H,m,ArH),7.387.40(1H,m,ArH),7.55(1H,dd,1=5.OHz,J2=1.3Hz,ArH),7.82(1H,dd,^=8.5Hz,J2=2.1Hz,ArH),8.058.06(1H,m,ArH),8.64(1H,s,ArH),9.11(1H,d,J=2.1Hz,NH)4-(2-(4-(2,3,4-三甲氧基芐基)哌嗪-l-基)乙氧基)-3-(3-噻吩酰胺基)苯甲酸(VIII-21)以VII-21為原料,操作同V-1,得黃色油狀物,收率77.5%.'HNMR(300MHz,CDC13),S(ppm):2.702.95(8H,m,-n二n-),3.01(2H,t,J=5.4Hz,_CH2-),3.88(2H,s,_CH2_),3.90(3H,s,_OCH3),3.91(3H,s,_OCH3),3.92(3H,s,-OCH3),4.15(2H,t,J=5.4Hz,_CH2_),6.786.84(2H,m,ArH),7.027.05(1H,m,ArH),7.22(1H,d,J=8.5Hz,ArH),7.59(1H,dd,^=5.1Hz,J2=1.1Hz,ArH),7.88(1H,dd,J!=8.5Hz,J2=1.8Hz,ArH),8.13(1H,m,ArH),8.42(1H,s,ArH),9.75(1H,s,NH)以VIII-21為原料,操作同I-l,得白色固體,收率63X,m.p.167_170°C。IR(cm—0:3380,2938,1678(C=0),1531,1496,1358,1272,1095(0CH3),1011,790^NMR(300MHz,CDC13),S(ppm):2.402.60(8H,m-n二n-),2.80(2H,t,J=5.lHz,_CH2_),3.44(2H,s,_CH2_),3.85(3H,s,_OCH3),3.86(3H,s,_OCH3),3.87(3H,s,-OCH3),4.23(2H,t,J=5.lHz,_CH2_),6.62(1H,d,J=8.5Hz,ArH),6.936.98(2H,m,ArH),7.367.39(1H,m,ArH),7.53(1H,dd,J!=5.lHz,J2=1.2Hz,ArH),7.96(IH,dd,J!=8.5Hz,J2=2.lHz,ArH),8.058.06(1H,m,ArH),8.75(1H,s,ArH),8.77(1H,d,J=2.OHz,NH)MS(ESI(+)70V)m/z597.3[M+H]+Anal.Calcd.forC29H36N606S()5H20:C57.50,H6.16,N13.87;Found:C57.78,H6.32,N13.66實施例54-(2-(4-(2,3,4-三甲氧基節(jié)基)哌嗪_1_基)乙氧基)_3_(3_甲基_2_噻吩酰胺基)苯甲酰胍(1-22)的制備4-(2-(4-(2,3,4-三甲氧基節(jié)基)哌嗪_1_基)乙氧基)_3_(3_甲基_2_噻吩酰胺基)苯甲酸乙酯(VII-22)以VI-1和3-甲基-噻吩-2-甲酰氯為原料,操作同VII-5,得白色固體,收率34.1%,m.p.122-125°C。丄HNMR(300MHz,CDC13),S(ppm):1.39(3H,t,_CH3,J=7.2Hz),2.402.60(8H,m,-n二n-),2.63(3H,s,_CH3),2.82(2H,t,J=5.5Hz,_CH2_),3.45(2H,s,-CH2_),3.85(3H,s,_0CH3),3.86(3H,s,_0CH3),3.87(3H,s,_0CH3),4.24(2H,t,J=5.5Hz,-CH2_),4.36(2H,q,J=7.2Hz,_CH2_),6.62(1H,d,J=8.6Hz,ArH),6.936.97(3H,m,ArH),7.35(lH,d,J=5.OHz,ArH),7.81(1H,dd,^=8.6Hz,J2=2.lHz,ArH),8.46(1H,s,ArH),9.IO(IH,d,J=2.lHz,NH).4-(2-(4-(2,3,4-三甲氧基節(jié)基)哌嗪_1_基)乙氧基)_3_(3_甲基_2_噻吩酰胺基)苯甲酸(VIII-22)以VII-22為原料,操作同V-l,得白色固體,收率89.0%,m.p.72-75°C。工HNMR(500MHz,CDC13),S(ppm):2.59(3H,s,_CH3),2.652.75(8H,m,畫n二n-),2.89(2H,t,J=4.9Hz,-CH2_),3.64(2H,s,_CH2_),3.85(3H,s,_0CH3),3.86(3H,s,_0CH3),3.87(3H,s,-0CH3),4.23(2H,t,J=4.9Hz,_CH2_),6.64(1H,d,J=8.5Hz,ArH),6.87(1H,d,J=8.6Hz,ArH),6.90(1H,d,J=4.9Hz,ArH),7.02(1H,d,J=8.5Hz,ArH),7.32(1H,d,J=4.9Hz,ArH),7.78(1H,dd,^=8.5Hz,J2=1.5Hz,ArH),8.39(1H,s,ArH),8.95(1H,d,J=1.4Hz,NH)以VIII-22為原料,操作同I-l,得白色固體,收率65X,m.p.122_125°C.IR(cm—0:3427,3341,2936,1702(C=0),1535,1462,1350,1271,1099(0CH3),1036,750'HNMR(500MHz,CDC13),S(ppm):2.352.55(8H,m,-N二N-),2.63(3H,s,_CH3),2.78(2H,t,J=5.5Hz,_CH2_),3.41(2H,s,_CH2_),3.85(3H,s,_0CH3),3.86(3H,s,_0CH3),3.87(3H,s,-0CH3),4.23(2H,t,J=5.5Hz,_CH2_),6.62(1H,d,J=8.5Hz,ArH),6.936.97(3H,m,ArH),7.37(1H,d,J=5.OHz,ArH),7.95(1H,dd,^=8.6Hz,J2=2.1Hz,ArH),8.5Q(1H,s,ArH),8.74(1H,d,J=2.OHz,NH).13CNMR(500MHz,CDC13),S(卯m):16.1,52.7(哌嗪C),53.6(哌嗪C),56.0,56.5,60.8,61.2,107.0,111.7,121.6,124.0,125.1,126.4,126.6,127.9,132.1,132.3,140.9,142.3,150.7,152.7,152.9,161.3,163.2,176.8(C=0)MS(ESI(+)70V)m/z611.3[M+H]+.Anal.Calcd.forC3。H38N606SH20:C57.31,H6.41,N13.37;Found:C57.27,H6.30,N13.06實施例64-(2-(4-(2,3,4-三甲氧基節(jié)基)哌嗪-l-基)乙氧基)-3-(4-甲基苯磺酰胺基)苯甲酰胍(1-23)的制備4-(2-(4-(2,3,4-三甲氧基節(jié)基)哌嗪-l-基)乙氧基)-3-(4-甲基苯磺酰胺基)苯甲酸乙酯(VII-23)的制備取VI-1和4-甲基苯磺酰氯為原料,操作同VII-5,得黃色油狀物,收率37.9X.'HNMR(300MHz,CDC13),S(ppm):1.38(3H,t,J=7.lHz,_CH3),2.35(3H,s,_CH3),2.452.70(IOH,m,-n二n-,-CH2_),3.54(2H,s,_CH2_),3.86(3H,s,_0CH3),3.87(3H,s,-0CH3),3.89(3H,s,_0CH3),4.01(2H,t,J=5.4Hz,_CH2_),4.34(2H,q,J=7.1Hz,_CH2_),6.64(1H,d,J=8.5Hz,ArH),6.83(1H,d,J=8.5Hz,ArH),7.02(1H,d,J=8.5Hz,ArH),7.17(2H,d,J=8.4Hz,ArH),7.64(2H,d,J=8.4Hz,ArH),7.75(1H,dd,^=8.5Hz,J2=2.lHz,ArH),8.19(1H,d,J=2.lHz,ArH).4-(2-(4-(2,3,4-三甲氧基節(jié)基)哌嗪-l-基)乙氧基)-3-(4-甲基苯磺酰胺基)苯甲酸(VIII-23)的制備以VII-23為原料,操作同V-l,得白色固體,收率87.0%.m.p.52-55°C。工HNMR(500MHz,CDC13),S(ppm):2.32(3H,s,_CH3),2.56(2H,t,J=5.3Hz,_CH2_),2.602.85(8H,m,-n二n-),3.71(2H,s,_CH2_),3.87(3H,s,_OCH3),3.89(3H,s,_OCH3),3.90(3H,s,-OCH3),3.97(2H,t,J=5.3Hz,_CH2_),6.66(1H,d,J=8.5Hz,ArH),6.78(1H,d,J=8.5Hz,ArH),7.09(1H,d,J=8.5Hz,ArH),7.13(2H,d,J=8.3Hz,ArH),7.59(2H,d,J=8.3Hz,ArH),7.77(1H,dd,J丄=8.5Hz,J2=2.OHz,ArH),8.21(1H,d,J=2.OHz,ArH)以VIII-23為原料,操作同I-l,得白色固體I-23,收率66X,m.p.202_205°C。IR(cm—0:3348,2928,1695(C=0),1499,1466,1320,1269,1095(OCH3),1012,664;丄HNMR(300MHz,DMS0_d6),S(ppm):2.31(3H,s,_CH3),2.452.55(10H,m,-n二n-,-CH2_),3.42(2H,s,_CH2_),3.76(3H,s,_OCH3),3.77(3H,s,_OCH3),3.78(3H,s,_OCH3),3.87(2H,t,J=5.2Hz,-CH2_),6.76(1H,d,J=8.6Hz,ArH),6.93(1H,d,J=8.6Hz,ArH),6.98(1H,d,J=8.6Hz,ArH),7.27(2H,d,J=8.lHz,ArH),7.53(2H,d,J=8.lHz,ArH),7.83(1H,d,J=8.6Hz,ArH),8.04(1H,d,J=2.OHz,ArH),9.80(1H,bs,NH)13CNMR(300MHz,CDC13),S(ppm):21.5,52.1(哌嗪C),53.0(哌嗪C),56.3,56.5,60.8,61.3,68.1,107.0,116.1,116.2,120.9,123.8,125.3,127.1,127.8,128.2,129.3,129.4,136.7,142.4,143.5,152.7,153.0,153.4,161.8,164.5,175.2(C=0).MS(ESI(+)70V)m/z641.3[M+H]+Anal.Calcd.forC31H40N607S:C58.ll,H6.29,N13.11;Found:C57.83,H6.45,N12.76。以VI-1和2-氯苯甲酰氯為原料,類似化合物1-5的方法,得到化合物I數(shù)據(jù)見表2。以VI-1和2-溴苯甲酰氯為原料,類似化合物1-5的方法,得到化合物I數(shù)據(jù)見表2。以VI-1和2-氟苯甲酰氯為原料,類似化合物1-5的方法,得到化合物I數(shù)據(jù)見表2。以VI-1和2-碘苯甲酰氯為原料,類似化合物1-5的方法,得到化合物I數(shù)據(jù)見表2。實施例74-(3-(4-(2,3,4-三甲氧基芐基)哌嗪-l-基)丙氧基)-3-(2-硝基苯甲酰胺基)苯甲酰胍(1-28)的制備3_硝基-4-(3-溴丙氧基)苯甲酸乙酯(III-2)取3-硝基-4-羥基苯甲酸乙酯(n-l)5g(0.0237mol),溶于70ml無水乙腈中,攪拌溶解,加入16g研細(xì)的碳酸鉀粉末,攪拌下一次性投入BrCH2CH2CH2Br18.9g(0.094mol),升溫至回流,反應(yīng)4h。將反應(yīng)液過濾,旋干濾液,柱層析(洗脫劑石油醚丙酮=8:1)得黃色油狀物4.7g,產(chǎn)率59.7%,直接投入下步反應(yīng)。3-硝基-4-(3-(4-(2,3,4-三甲氧基芐基)哌嗪_1_基)丙氧基)-苯甲酸乙酯(IV-2)取III-2為原料,操作同IV-1,得黃色固體,收率83.4%,m.p.89-92°C。工HNMR(300MHz,CDC13),S(ppm):1.40(3H,t,J=7.1Hz,_CH3),2.02(2H,m,_CH2_),2.452.60(IOH,m,-n二n-,-CH2_),3.48(2H,s,_CH2_),3.85(3H,s,_0CH3),3.87(3H,s,_0CH3),3.88(3H,s,-0CH3),4.23(2H,t,J=6.2Hz,_CH2_),4.38(2H,q,J=7.lHz,_CH2_),6.62(1H,d,J=8.5Hz,ArH),6.98(1H,d,J=8.5Hz,ArH),7.13(1H,d,J=8.8Hz,ArH),8.18(1H,dd,1=8.8Hz,J2=2.2Hz,ArH),8.47(1H,d,J=2.lHz,ArH).3-氨基-4-(3-(4-(2,3,4-三甲氧基芐基)哌嗪_1_基)丙氧基)-苯甲酸乙酯(VI-2)以IV-2為原料,操作同VI-1,得淡黃色固體,收率98%,m.p.182-185°C。工HNMR(300MHz,CDC13),S(ppm):1.36(3H,t,J=7.lHz,_CH3),2.01(2H,m,_CH2_),2.452.60(IOH,m,-n二n-,-CH2_),3.48(2H,s,_CH2_),3.85(3H,s,_OCH3),3.87(3H,s,_OCH3),3.88(3H,s,-0CH3),4.09(2H,t,J=6.3Hz,_CH2_),4.31(2H,q,J=7.lHz,_CH2_),6.62(1H,d,J=8.6Hz,ArH),6.78(1H,d,J=8.6Hz,ArH),6.98(1H,d,J=8.5Hz,ArH),7.38(1H,d,J=2.lHz,ArH),7.44(1H,dd,^=8.4Hz,J2=2.lHz,ArH).4-(3-(4-(2,3,4-三甲氧基芐基)哌嗪-l-基)丙氧基)-3-(2-硝基苯甲酰胺基)苯甲酸乙酯(VII-28)取VI-2和2-硝基苯甲酰氯為原料,操作同VI1-5,得到黃色油狀物,收率33.8%.'HNMR(300MHz,CDC13),S(ppm):1.39(3H,t,J=7.lHz,_CH3),2.0(2H,m,_CH2_),2.402.55(IOH,m,-iCn-,-CH2_),3.51(2H,s,_CH2_),3.85(3H,s,_OCH3),3.87(3H,s,-OCH3),3.88(3H,s,-0CH3),4.15(2H,t,J=6.3Hz,_CH2_),4.37(2H,q,J=6.9Hz,-CH2_),6.63(1H,d,J=8.7Hz,ArH),6.937.01(2H,m,ArH),7.617.76(3H,m,ArH),7.85(1H,dd,1=8.7Hz,J2=1.8Hz,ArH),8.098.11(2H,m,ArH),9.04(1H,d,J=1.5Hz,NH)4-(3-(4-(2,3,4-三甲氧基芐基)哌嗪-l-基)丙氧基)-3-(2-硝基苯甲酰胺基)苯甲酸(VIII-28)以VII-28為原料,操作同V-l,得白色固體,收率67.5%,m.p.85-87°C。工HNMR(300MHz,CDC13),S(ppm):2.08(2H,m,_CH2_),2.502.95(10H,m,-n二n-,-CH2_),3.50(2H,s,-CH2_),3.84(3H,s,_OCH3),3.85(3H,s,_OCH3),3.86(3H,s,_OCH3),4.13(2H,t,J=6.3Hz,-CH2-),6.61(lH,d,J=8.7Hz,ArH),6.79(lH,d,J=8.7Hz,ArH),6.97(lH,d,J=8.7Hz,ArH),7.597.76(3H,m,ArH),7.968.04(2H,m,ArH),8.35(1H,s,ArH)8.44(1H,s,緣以VIII-28為原料,操作同I-l,得黃色固體,收率35X,m.p.139_142°C。IR(cm—":3376,2939,2821,1673(C=0),1601,1528,1494,1346,1267,1096(0CH3),1010,786丄匪R(500MHz,CDC13),S(ppm):1.99(2H,m,_CH2_),2.452.70(IOH,m,-n二n-,-CH2_),3.47(2H,s,_CH2_),3.85(3H,s,_OCH3),3.86(3H,s,_OCH3),3.87(3H,s,-OCH3),4.12(2H,t,J=6.3Hz,_CH2_),6.63(1H,d,J=8.5Hz,ArH),6.946.98(2H,m,ArH),7.617.74(3H,m,ArH),7.95(1H,d,J!=8.5Hz,ArH),8.05(1H,d,J=8.5Hz,ArH),8.25(1H,s,NH),8.73(1H,s,ArH)13CNMR(300MHz,CDC13),S(卯m):26.4,52.6(哌嗪C),53.1(哌嗪C),55.9,56.3,60.7,61.1,67.2,107.0,110.9,122.1,123.6,124.6,125.1,125.4,127.1,128.6,130.1,131.0,132.3,133.8,142.2,146.8,151.4,152.5,152.9,161.8,164.5,175.2(C=0).MS(ESI(+)70V)m/z650.4[M+H]+Anal.Calcd.forC32H39N708:C59.16,H6.05,N15.09;Found:C58.85,H6.30,N15.12以VI-2和2,4-二氯苯甲酰氯為原料,類似化合物1-5的方法,得到化合物1-29,光譜數(shù)據(jù)見表2。以VI-2和4-甲氧基苯甲酰氯為原料,類似化合物1-5的方法,得到化合物1-30,光譜數(shù)據(jù)見表2。以VI-2和2-甲基-3-硝基苯甲酰氯為原料,類似化合物1-5的方法,得到化合物I-31,光譜數(shù)據(jù)見表2。以VI-2和4-氰基苯甲酰氯為原料,類似化合物1-5的方法,得到化合物1-32,光譜數(shù)據(jù)見表2。以VI-2和4-乙基苯甲酰氯為原料,類似化合物1-5的方法,得到化合物1-33,光譜數(shù)據(jù)見表2。以VI-2和2,6-二氯苯甲酰氯為原料,類似化合物1-5的方法,得到化合物I_34,光譜數(shù)據(jù)見表2。以VI-2和4-三氟甲基苯甲酰氯為原料,類似化合物1-5的方法,得到化合物I-35,光譜數(shù)據(jù)見表2。以VI-2和苯甲酰氯為原料,類似化合物1-5的方法,得到化合物I-36,光譜數(shù)據(jù)見表2。實施例84-(3-(4-(2,3,4-三甲氧基芐基)哌嗪_1_基)丙氧基)_3_(3_噻吩酰胺基)苯甲酰胍(1-37)的制備4-(3-(4-(2,3,4-三甲氧基芐基)哌嗪_1_基)丙氧基)_3_(3_噻吩酰胺基)苯甲酸乙酯(VII-37)取VI-2和噻吩-3-甲酰氯為原料,操作同VII-5,得黃色油狀物,收率30.6%。工HNMR(300MHz,CDC13),S(ppm):1.40(3H,t,J=7.2Hz,_CH3),2.04(2H,m,_CH2_),2.502.74(10H,m,-N二N-,-CH2_),3.48(2H,s,_CH2_),3.85(3H,s,_0CH3),3.87(3H,s,_0CH3),3.88(3H,s,-0CH3),4.17(2H,t,J=6.3Hz,_CH2_),4.35(2H,q,J=7.2Hz,_CH2_),6.63(1H,d,J=8.4Hz,ArH),6.956.99(2H,m,ArH),7.417.48(2H,m,ArH),7.937.97(2H,m,ArH),8.35(1H,s,ArH),9.16(1H,s,NH)4-(3-(4-(2,3,4-三甲氧基芐基)哌嗪-l-基)丙氧基)-3-(3-噻吩酰胺基)苯甲酸(VIII-37)以VII-37為原料,操作同V-l,得白色固體,收率79.9%,m.p.98-101°C.丄HNMR(300MHz,CDC13),S(ppm):2.1(2H,m,_CH2_),2.552.80(10H,m,-n二n-,-CH2_),3.70(2H,s,_CH2_),3.85(3H,s,_OCH3),3.86(3H,s,_OCH3),3.87(3H,s,-OCH3),4.12(2H,t,J=6.3Hz,_CH2_),6.63(1H,d,J=8.4Hz,ArH),6.73(1H,d,J=8.7Hz,ArH),6.97(1H,d,J=8.4Hz,ArH),7.387.41(1H,m,ArH),7.63(1H,dd,J丄=8.4Hz,J2=1.8Hz,ArH),7.697.70(1H,m,ArH),8.29(1H,d,J=1.8Hz,ArH),8.40(IH,s,ArH),9.5(1H,s,NH).以VIII-37為原料,操作同I-l,得白色固體,收率53X,m.p.183_185°C。IR(cm—":3397,2937,2849,1672(C=0),1604,1535,1494,1358,1267,1095(OCH3),1036,797丄匪R(300MHz,CDC13),S(ppm):2.05(2H,m,_CH2_),2.352.60(IOH,m,-n二n-,-CH2_),3.49(2H,s,_CH2_),3.85(3H,s,_OCH3),3.87(3H,s,_OCH3),3.88(3H,s,-OCH3),4.17(2H,t,J=6.3Hz,_CH2_),6.63(1H,d,J=8.4Hz,ArH),6.966.99(2H,m,ArH),7.417.48(2H,m,ArH),7.937.98(2H,m,ArH),8.26(1H,s,ArH),8.7(1H,s,NH).MS(ESI(+)70V)m/z611.4[M+H]+.Anal.Calcd.forC3。H38N606S()5H20:C58.14,H6.34,N13.56;Found:C58.02,H6.42,N13.39以VI-2和噻吩-2-甲酰氯為原料,類似化合物1-5的方法,得到化合物1-38,光譜數(shù)據(jù)見表2。以VI-2和3-甲基-噻吩-2-甲酰氯為原料,類似化合物1-5的方法,得到化合物I-39,光譜數(shù)據(jù)見表2。以VI-2和4-甲基苯磺酰氯為原料,類似化合物1-5的方法,得到化合物I-40,光譜數(shù)據(jù)見表2。實施例9片劑取實施例12方法制得的化合物1-46lOOmg與淀粉200mg,糊精lOOmg混合,用適量30%乙醇作濕潤劑,制成軟材,常規(guī)方法制粒,加入適量硬脂酸鎂混合,制成片劑。表2.部分目的化合物的光譜數(shù)據(jù)代'HNMR(CDCl,),5(ppm)IRv/c附.'ESI德附/z號3406,1699,62.51—2.58(8H,m,-N二N—)'2.78(2H,t.J=5.7Hz,-CH2-),3.47(2H,s,-CH2-),3.84(3H,s'-OCH3),1-21579,1258,472.4[M+H]+3.86(3H,s,-OClI3),3.87(3H,s,-OCH3),4.11(2H,t,-CHr,J=5.7Hz),6.62(lH,d,J=8.6Hz,1095,764ArH)'6.85(2H,d'J-8.8Hz,ArH),6.96(lH,d,JL5Hz,ArH),8.05(2H,d,J'-8.8Hz,ArH)3379,1700,"2.502.67(8H,mrN"N_),2.88(2H,t,-CH2-,J=5,7Hz),3.49(2H,s'-CH2-),3.85(3H,s,-OCH3),1-31499,1264,550.2[M+H]十3.86(3H,s,-OCH3),3.88(3H,s,-OCH3),4.20(2H,t,CHr,J-5.7Hz),6.62(lH,d,ArH,J=8.6Hz),6.1101,75186(lH,d,ArH,J-&7Hz),6.98(lH,d,ArH,J=8.5Hz),8.070H,dd,J=8.5Hz,J2=2,0Hz,ArH),3443,1704,I醫(yī)41467,1272,1098,7423383,1679,1-6訓(xùn),1497,1257,7093326.1650,1-7願,1534,1347,7883387,2824,1-81676,1494,1095,7893372,1671,1-91494,1097,7863423,1669,1466,1348,1-101095,7623440,1679,1-121493,1346,1097,7883385,1659,[-13,,1347,1096,7888.38(1H,d,ArH,J=2.0Hz)。2.542.63(8H,m,_N"N-),2.88(2H,t,-CH2-,J=5.6Hz),3.48(2H,s,-CH2-),3.85(3H,s,-OCH3),630.0[M+H〗+3-86(3H,s,-OCH3),3.88(3H,s,-OCH3),4.14(2H,t,-CH2,J=5,6Hz),6.63(1H,d,h8.6Hz,ArH),6.訴(UI,d,ArH,J=8.6Hz),8,26(2H,s,ArII)fr2.352.57(8H,m:),2.76(2H,t,J=5.4HvCHr),3.39(2H,s,-CH2-),3.84(3H,s,-OCH3),591.4[M+H1+,8.92(1H,s,NH)."2.402.65(8H,m,—N^N—),2.78(2H,t,J-5.5Hz,-CH2-),3.40(2H,s7-CH2-),3.84(3H,s,-OCH3),3.8621.3[M+H]+d,J=8.6Hz,ArH),6.926.95(2H,m,ArH),6.99(2H,dd,J產(chǎn)8.8Hz,J2-1.9Hz,ArH),7.87(2H,dd,J產(chǎn)8.8Hz,Jf2.0Hz,ArH),7.94(lH,dd'J產(chǎn)8.6Hz,J2=2.0Hz,ArH),8.7(lil,cU=2.0Hz;,ArHX62.402.60(8H,m"二N-),2.45(3H,s,-CH3),2.78(2H,t,J=5.4Hz,-CHr),3.40(2H,s,-CHr),3.84(3H,s,-OCH3),3.85(3H,s,-OCH3),3.86(3H,s,-OCH3),4.24(2H,t,J=5.4Hz,-CH2-),6.62605.4[M+H;T(lH,d,J=8.5Hz,ArH),6.94(lH,dJ=8.5Hz,ArH),6.98(lH,d,J=8.6Hz,ArH),7.30(2H,d,P8.1H^ArH),7.80(2H,d,JUHz,ArH),7.97(1H,dcU產(chǎn)8.6Hz;,J2-l,9Hz;ArH),8.78(2H,s,ArH,卿力2.252,50(8H,m,—N"N-7(2H,t,J=5.4Hz,-CH2-),3-33(2H,s,-CH2),3.84(3H,s,-OCH3),3,86(3H,s,-OCH3),3.87(3H,s,-OCH3),4.21(2H,t,J-5.4Hz,-CH2),6.62(1H,d,659.3[M+H〗+J=8.6Hz,ArH),6.91(1H,d,J=&5Hz,ArH),7.00(1H,d,J-8.6Hz,ArH),7.37(lH,dd,J產(chǎn)8.3Hz,J2=2.0Hz,ArH),7.50(lH,d,W.9Hz,Ar1),7.71(lH,,d,>=8.3Hz,ArH),7.98(1H,dd,J產(chǎn)8.6Hz,J2=2.0Hz,ArH),8.77(lH,d,J=L9Hz,ArH),9.33(IH,s,NH)。2.552.70(8H,m,_NJ—),2.89(2H,t,J=5.7H2,-CH2-),3.53(2H,s,-CHr),3.85(3H,s,-OCH3),3.86(3H,s,-OCH3),3.87(3H,s,-OCH3),4、l5(3H,s,-OCH3),4.25(2H,q,〗=5.7Hz,-CHr),6.63(lH,d,風(fēng)4Hz,ArH),6.96巧.03(2H,m,ArH〕,7.65-7.71(1H,m,ArH),8.07(1H,d,戶8.1Hz,ArH),9.12(lH,s,ArH),9.17(1H,s,NH)。1.28(3H,t,J-7.5Hz,-CH3),2.402.60(8H,m,—N"N—),2.722,78(4H,m,-CHr),3.40(2H,s,-CH2-),3.84(3H,vOCH3),3.85(3H,s,-OCH3),3.86(3H,s,-OCH3),4二5(2H,t,J=5.4Hz,fM+Hf-CH2-),6,62(lH,d,J=8.7Hz,ArH)'6.93(lH,d,J=8.7Hz,ArH),6.99(lH,d,J=8.7Hz,ArH),7.34(2H,d,J-8.lHz,ArH),7.84(2H,d,J=8.lHz,ArH),7.97(lH,d,J-8.4Hz,ArH),8-71(lHAArH),8.82(m,s,卿。2.352.65(UH,m,_tCN_,-CH3),2.67(2H,t,J=5.4Hz,-CHr),3.34(2H,s,-CH2-),3.78(3H,s,648.3[M-H]--OCH3),3.80(3H,s,-OCH3),3.8U3H,s,-OCH3),4.06(2H,t,J=5.4Hz,-CHr),6.57(lH,d,J=8.7Hz,ArH),6,826.86(2H,m,ArH),7.747.90(4H,m,Arli),8.66(1H,s,ArH),9.35(lH,s,NH)675.3[M+H]+1-143397,歸,1494,1348,麵,7882938,2823,1-151689,1494,1095,7893396,1652:1-161495,1344,1096,7893420,16381-171462,1350,,,7893431,1667,1-181495,1270,1010,7卯3421,2柳,1-191689,1494,1096,7883376,2942,1-201706,1462,1264,7993433,2821,1-241677,1496,1267,789605.3[M+H]+687.2[M-H]-"2.252.45(8H,m,"-"AI^IUMSI^-CJWWPHa-CHJ^Ha-CFVX-S.MPH's,-OCH3),3.85(3H,s,-OCH3),3.86(3H,s,-OCH3),4,23(2H,t,J=4.8Hz,-CH2-),650.2[M+H+6.63(lH,d,J=8.7Hz,ArH),6.87(lH,d,J=8.4Hz,ArH),7.05(IH,d,J-8.4Hz,緒),7,46(1H,t,J=7.8Hz,ArH),7.76(1H,d,J尸7.5Hz,ArH),7,95(lH,d,J=7.8Hz,ArH),8.02(IH,d,J=8.4Hz,ArH),8.69(lH,s,ArH),9.29(1H,s,NH)"2.202.60(8H,m,陽n一n-),2.72(2H,t,J=5.1Hz,-CHr),3.29(2H,s,-CH2-),3.73(3H,s,616.2[M+H〗+8.4Hz,ArH),6.89(lH,d,J=8.4Hz,ArH),7.13(1H,d,J-8.4Hz,ArH),7.938.09(5H,m,ArH),8.36(lH,s,ArH>,9.78(1H,s卿"2.352.6(J(UH,m,,二N—,CH3),2.78(2H,l,J-5.4Hz,-CH2-),3.38(2H,s,-CHr),3.84(3H,s,-Oai3):3,85(3H.s,-OCH3),3.86(3H,s,-OCH;0,4.24(2H,t,J=5.4Hz,-CH2-),6.61(lH,cU=8.4Hz,ArH),6.92(]H,d,J=8.4Hz,ArH),6.99(IH,d,J=8.7Hz,ArH),7.36~7.38(2H,m,ArH),7.667.70(2H,m,ArH〕,7,98(1H,dd,J,8,7Hz,J2-1.8Hz,ArH),8.78(lH,d,片I.8Hz,ArH),8.85(1H,s,NH)"2.l9~2.51(SH,ni,_N"N—),2.60(2H,t'h5.4HzrCH2-),3.27(2H,s,-CH2-),3.85(3H,vOCH3〉,3.86(3H,s,-OCH3),3.87(3H,s,-OCH3),3.98(3H,s,-OCH3),4.23(2H,t,J=5.4Hz,CH2-),6.62(m,d,J=8.7H7,ArH),6.91(lH,d,J=8,7Hz,ArH),7.05(lH,d,J=8,7Hz,ArH),7.2(1H,d,J=8.7Hz,ArH),7.42(1H,d,J^.7Hz,ArH),8,03(lIidd,J產(chǎn)8,7H2,J2-2.1HAArH),S.65(lH,s,雄〉,9都H,s,NH)"2.20(3H,vCH3),2.3(K2.50(8H,mTNwN—),2.70(2H,t,J-5,4Hz,-CHr),3.50(2H,s,-CHr),3.85(3H,s,-OCH3),3.87(3H,s,-OCH3),3.88(3H,s,-OCH3),4.19(2H,t,J=5.4Hz,-CH2-)-6.62(lH,d,J-8.5Hz,ArH),6.936.97(2H,m,ArM),7,89(lH,dd,J產(chǎn)8.6Hz,J產(chǎn)2.1Hz,ArH),8.4(lH,d,J=2.1Hz,ArH),8.71(lH,s,NH)。2.382.53(8H,m,-N二",2.78(2H,t,-CH2-,J=5,lHz,),3.38(2H,s,-CHr).3.即H,s,-OCH3>,3.85(3H,s,-OCH3),3.86(3H,s,-OCH3),4.24(2H,t,-CH2-,J-5.1Hz),6.62(1H,d,ArH,J=8.7Hz),6.92(lH,d,ArH,〗=8.7Hz),7.01(lH,d,ArH,J=8.7Hz),7.78(2H,d,ArH,J=8,lHz),7.988.04(3H,ni,ArH),8.81(lH,s,ArH),9,03(lH,s,NH)"2.452.60(8H,m,一nJ—),2.82(2H,t,J=5.1Hz,-CH2-),3.44(2H,s,-CHr),3,85諷s,-OCH3〉,3.86(3H,s,-OCH3),3.87(3H,s,-OCH3),4.24(2H:t:J-5.4Hz,-CH2-),597.M+H]+6.62(]H,d,J=8.4Hz,ArH),6.93一.98(2H,m,ArH),7.127.14(IH,m,ArH),7.57(lH,d,;N5,lIiz,ArH),7.697.70(lH,m,ArH),7,96(1H,dd,J產(chǎn)8,4Hz,Jfl.8Hz,ArH),8.71(lH,s,ArH),8.76(1H,s,NH)"2.252.45(8H,m,—N二N—),2.68(2H,t,-CH2,J=5.4Hz,),3.31(2H,s,-CH2>,3.84(3H,s,-OCH3),3.85(3H,s,OCH3),3.86(3H,s,-OCH3),4.22(2H,t,-CH2,J=5.4Hz,),6.62(1H,d,ArH,(1H,d,ArtU產(chǎn)8.7Hz),8.01(lH,d,ArH,J=8.7Hz),8.82(1H,s,ArH),9.27(H,s,NH)529.4[M+H]+659.4[M+H]+625,[M+H〗+1-251-261-271-291-301-311-321-333428,2821,1676,1496,1267,7893419,2937,1574,1494,1096,7853405,2937,1528,1346,1095J863396,1656,1464,1348,1097,7863440,讓,1463,1384,1095,7433376,2942,1706,1344,1097,7993443,1696,1466,1349,1098,7593425,1673,1494,1350,1095,788671.3[M+H〗+609.5[M+H]+"2.262.41(8H,m,-N—N-),2.63(2H,t,-CH2,J-5.1Hz,),3.26(2H,s,-CH2),3.84(3H,s,-OCH3),3.85GH,s,-OCH》,3.86(3H,s,-OCH3),4,23(2H,t,-CH2,J=4.8Hz),6.62(lH,d,ArH,J=8,7Hz),6.90(lH,d,ArH,J=8.4Hz),7.04(IH,d,ArH,J=8.7Hz),7.347.46(2H,m,ArH),7.64^7.70(2H,m,ArH),S.01(1H,dd,ArH,J=8.4Hz,J-1.8Hz),8.65(H,d,ArH,M.8Hz),9.37(1H,s,麗)"2.442.56(8H,m,—),2.83(2H,t,-CH2,J".IHz,),3.42(2H,s,-CH2),3.84(3H,s,-OCH3),3.85(3H,s,-OCH3),3.86(3H,s,-OCH3),4.24(2H,t,-CH2,J=5-lHz),6.61(lH,d,ArH,J=8.4Hz),6.936.97(2H,m,ArH),7.14~7.35(2H,m,ArH),7.52(1H,d,ArH,J=8.4Hz),7.95(1H,d,ArH,J二8.7Hz),8.09(1H,d,ArH,J-8.4Hz),8.84(1H,s,ArH),9.32(1H,d,NH)。2,17~2.41(8H,m,),2.62(2H,t,-CH2,J=5.1Hz,),3.27(2H,s,-CH2),3.85(3H,s,-OCH3),3.86(3H,s,-OCH3),3.87(3H,s,-OCH3),4.22(2H山-CH2,J=5'lHz),6.62(lH,d,717.3[M+H;TM.2Hz),9.36(1H,s,麗)Y99(2H,nvCH2-),2,35~2.60(10H,m,+二^,-012-),3.48(2H,s,-CHr),3.85(3H,s,-OCH3),63.87(3H,s,-OCH3),3.88(3H,s,-OCH3〉,4,15(2H,t,J-6.4Hz,-CH2-),6.63(1H,d,JUHz,673.3[M+H]+ArH),6.966,99(2H,m,Ar印,7.390H,dd,J產(chǎn)8.4Hz,〗2=1.8Hz,ArH),7.49(1H,d,J=l-8Hz,ArH),7.77(1H,d,J二8.4Hz,ArH),7.99(lH,d,J二8.6Hz,ArH〉,8.57(1H,s,ArH),8,87(1H,s卿.62.05(2H,m,-CH2-),2.352.55(10H,m,-n二n—,-CH2-),3.49(2H,s,-CH2),3.86(3H,s,-OCH3),3.88(3H,s,-OCH3),3.89(3H,s,-OCH3),3"0(3H,s,-OCH3),4.18(2H,t,J-6.2Hz,-CH2-),6.64(lH,cU=8.5Hz,ArH),6.98~6.99(2H,m,ArH),7.02(2H,d,J=8.8Hz,ArH),7.86(2H,d,J-8.8Hz,ArH),7.95(1H,d,JN8.6Hz,ArH),8.35(1H,s,ArH),8.70(1H,s,NH).*2.01(2H,m,-CH2-),2.47~2.60(10H,m,_NuN-,-CH2-),3,50(2H,s,-CHr),3.85(3H,s,-OCH3),3.86(3H,s,-OCH3),3-87(3H,s,-OCH3),4.24(2H,t,J=6.4Hz,-CH2-),6,62(lH,d,664.4[M+H]+ArH,J=8.5Hz),635.4[M+H+630.4[M+H]+633.4[M+H]+ArH),8.05(1H,dd,J,-8.5Hz,J2^.;5Hz,ArH),8.17(iris,NH),9-0(lH,s,ArH)、05(2H,nvCH2-),2.572.61(IOH,m,-N"N—,-CH2-),3.54(2H,s,-CHr),3.85(3H,s,-OCH3),3.87(3H,s,-OCH3),3,88(3H,s,-OCH3),4,21(2H,t,J-6.5Hz,-CH2-),6.65(1H,d,J=8.5Hz,ArH),6.997.01(2H,rruArH),7.78(2H,d,J=8.0Hz,ArI4),7.988.02(3H,m,ArH),8.56(1H,s,ArH),9.06(1H,s,NH)."1.28(3H,t,J-7.5nz,-CH3),2.04(2H,m,-CH2-),2.50~2.54(10H,mrNwN-,-CHr),2.73(2H,q,J=7.5Hz,-CH2-),3.49(2H,s,-CH2-),3.85(3H,s,-OCH3),3.87(3H,s,-OCH3),3.88(3H,s,-OCHO,4.17(2H,t,J=6.3Hz,-CH2-),6,62(lH,d,J:8-7Hz,ArH),6.96一.99(2H,m,ArH),7.33(2H,d,J=8.4Hz,ArH),7.79(2H,d,J=8.4Hz,ArH),7.96(UI,dd,J產(chǎn)8.Iz,1-353435,1667,1496,1362,1096,7963420,1704,1464,1326,聽,7583366,1673,1-361465,1356,1095,7903445,1664,1-381495,1355,1097,7463424,1664,1-391492,1349'1095,7843353,1735,1-401495,1301,1093,767673.3[M+HJ+673.4[M+H]+J2=l.8Hz,ArH),8.42(1H,s,ArH),8.76(1H,d,J=1.8Hz,NH)."1.97(2H,m,-CHr),2.452-51(lOH,m,-N^N—,-CH2-),3.47(2H,s,-CH2-),3.85(3H,s,-OCH3),3.86(3H,s,-OCH3),3.87(3H,s,-OCH3),4,14(2H,t,J=6.3Hz,-CH2-),6,63(lH,d,J=8.4Hz,ArH),6.967.00(2H,m,ArH),7甲307.41(3H,m,ArH),8,01(2H,dd,J嚴(yán)8.7Hz,2-1.5Hz,ArH),8.70(lH,d,J=1.5Hz,NH)。2.04(2H,m,-CH2-),2.402.65(10H,m,_N"N-,-CH2-),3.49(2H,s,-CH2),3.85(3H,s,-OCH3),3.87(3H,s,-OCH3),3.88(3H's'-OCH3),4.18(2H,t,J=6.3Hz,-CH2-),6.63(1H,d,J=8.7Hz,ArH),6.967.01(2H,m,ArH),7.78(2H,<U=8.4Hz,ArH),7.978.02(3H,m,ArH),8.46(1H,s.ArH),8.81(lH,d,J=1.8Hz,NH).。2.02(2H,m,-CH2-),2.50~2.55(腿,m,一"—,-CH2-),3.49(2H,s,-CH2-),3.86(3H,s,-OCH3),3.87(3H,s,-OCH3),3.88(3H,s,-OCH3),4.16(2H,t,J=6.6Hz,-CH2-),6.63(lH,d,605.3[M+H]+J=8.7Hz,ArH),6.99(2H,d,J=8.7Hz,ArH),7.49~7.61(3H,m,ArH),7.88(2H,d,J=6.9HzArH),7.98(lH,dd,J產(chǎn)8.7Hz,Jf2.1Hz,ArH),8.45(lH,s,ArH),8.82(1H,s,NH).ff2.05(2H,m,-CH2-),2.52~2.83(lOH'm'-OvCHr)'3.49(2H,s,-CHr),3.85(3H,s,-OCH3),3.87(3H,s,-OCH3),3.88(3H,s,-OCH3),4.17(2H,t,J=6.3Hz,-CH2-),6.63(1H,d,J=8.7Hz,ArH),6.95~6.99(2H,m,ArH),7.13~7.16(lH,m,ArH),7.57~7.63(2H,m,ArH),7.95(lH,d,J=8.4Hz,ArH),8.34(lH,s,ArH),8.68(lH,s,NH).611.3[M+H]+'2.03(2H,m,-CH2-),2.28~2.40(lOH,m,一■,-CH2-),2.62(3H,s,-CH3),3.49(2H,s,-CH2-),625.3[M+H]+655.3[M+H]+6.63(1H,d'J=8.5Hz'ArH),6.95~6.99(3H,m'ArH),7.37(lH,d,J=4.9Hz,ArlI),7.96(lH,dd,J,-8.6Hz,J2-2.0Hz,ArH),8.29(lH^,ArH),9.09(lH,d,;H2.0Hz,NH)*1.74(2H,m,-CH2-),2.30-2.34(5H,m,-CH2-,-CH3),2.45~2.52(m,m,—N"N_),3.49(2H,s,-CH2-),3.79(2H,、J=6.4Hz,-CH2-),3.8S(3H,s,-OCH3),3.87(3H,s,-OCH3),3.88(3H,s,-OCH;),6.63(lH,d,J=8.6Hz,ArH),6.74(lH,d,J=8.5Hz,ArH),6.99(lH,d,J=8.5Hz,ArH),7.15(2H,d,J=8.0Hz,ArH),7.56(2H,d,J=8.3Hz,ArH)'7.89(lH,dd,h=8.6HzJ2=2.1Hz,ArH),8.22(lH,d,J=2.0Hz,ArH).300MHz;*:500MHz.權(quán)利要求通式(I)的化合物或其藥學(xué)上可接受的鹽其中n=2~5;R代表氫、氯、溴、二溴、硝基、C1~C6烷基磺酰胺基、對甲苯磺酰胺基、噻吩-1-甲酰胺基、噻吩-2-甲酰胺基、2-甲基噻吩-1-甲酰胺基、C1~C6烷基酰胺基或R1取代的苯甲酰胺基;其中R1代表氫、鹵素、硝基、氰基、三氟甲基、羥基、C1~C6烷基、C1~C6烷氧基或亞甲二氧基,R1基團(tuán)是單個取代、任意兩個同時取代或任意三個同時取代。F2009102640374C00011.tif2.權(quán)利要求1的化合物或其藥學(xué)上可接受的鹽,其中n=2。3.權(quán)利要求1的化合物或其藥學(xué)上可接受的鹽,其中R基團(tuán)處于酰胍基的間位。4.權(quán)利要求1的化合物或其藥學(xué)上可接受的鹽,其中R代表對甲苯磺酰胺基、噻吩-1-甲酰胺基、噻吩_2-甲酰胺基、2-甲基噻吩-1-甲酰胺基、2-硝基苯甲酰胺基、3-硝基苯甲酰胺基、4-硝基苯甲酰胺基、4-三氟甲基苯甲酰胺基、2-乙基苯甲酰胺基、2,4-二氯苯甲酰胺基、2_甲基-3-硝基苯甲酰胺基、2,4-二氯-5-甲氧基苯甲酰胺基或2-甲氧基-3,4,5-三氟苯甲酰胺基。5.權(quán)利要求1的化合物或其藥學(xué)上可接受的鹽,其中藥學(xué)上可接受的鹽為權(quán)利要求1的通式(I)化合物與下列酸形成的酸加成鹽鹽酸、氫溴酸、硫酸、碳酸、檸檬酸、琥珀酸、酒石酸、磷酸、乳酸、丙酮酸、乙酸、馬來酸、甲磺酸、苯磺酸、對甲苯磺酸、阿魏酸或煙酸。6.—種藥物組合物,其中含有權(quán)利要求l的通式(I)化合物或其藥學(xué)上可接受的鹽及藥學(xué)上可接受的載體。7.權(quán)利要求1的通式(I)化合物或其藥學(xué)上可接受的鹽在制備預(yù)防或治療與NHE1有關(guān)的疾病的藥物中的用途。8.權(quán)利要求7的用途,其中與NHE1有關(guān)的疾病是心律失常、心室纖維化、心肌梗死、心絞痛、心力衰竭、心肌缺血或再灌注引起的組織器官急慢性損傷。全文摘要本發(fā)明涉及藥物化學(xué)領(lǐng)域,具體涉及一類苯甲酰胍-曲美他嗪的偶聯(lián)物(I)、其制備方法及其醫(yī)藥用途,其中R的定義同說明書,研究發(fā)現(xiàn),本發(fā)明的結(jié)構(gòu)式I化合物具有預(yù)防或治療與NHE1有關(guān)的疾病的功效,特別是可作為抗心肌缺血再灌注損傷藥物。文檔編號A61P9/10GK101747292SQ20091026403公開日2010年6月23日申請日期2009年12月29日優(yōu)先權(quán)日2009年12月29日發(fā)明者任淑娟,姜向敏,張國敏,徐云根,惲亞軍,李林林,楊小治,許超,龔國清申請人:中國藥科大學(xué)